Dianon/Aprogenex
This article was originally published in The Gray Sheet
Executive Summary
Dianon to purchase approximately $700,000 of Houston, Texas-based Aprogenex' convertible preferred stock and warrants to purchase additional shares of convertible preferred stock as part of a strategic alliance in genetic testing. Under the terms of the definitive agreement, announced June 9, Stratford, Connecticut-based Dianon gains an exclusive, limited term license to Aprogenex' development stage DNA probe technology for identifying "certain chromosome abnormalities in fetal cells separated from the maternal circulation." The testing services firm also gains the "right of first refusal for any exclusive license to future genetic technologies developed by Aprogenex." The deal also includes license fees and royalty payments that were not disclosed. In conjunction with the agreement, Dianon President and Co-CEO Jack Davis will become a member of Aprogenex' board of directors.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.